# The Multi-omics Vaccine Evaluation (MOVE) Consortium

> **NIH NIH P01** · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $1,778,269

## Abstract

PROJECT SUMMARY
An HIV vaccine represents our best opportunity for eliciting durable, protective immunity and ending the
decades-long AIDS pandemic. To be successful, an antibody-based HIV vaccine must reliably induce broadly
neutralizing antibodies (bnAbs), most likely via a series of immunogens or mixtures of immunogens delivered
sequentially. To avoid viral escape, bnAbs of at least 2-3 distinct specificities must be induced concurrently.
Thus, a more holistic view of HIV vaccine composition would resemble a matrix of immunogens rather than a
sequence. Constructing a single set of immunogens that reliably induce breadth against just one epitope is a
daunting challenge. Succeeding in the exponentially more difficult task of assembling a cohesive immunogen
matrix will require significant improvements in the speed and granularity with which we can design and evaluate
vaccines. Here, we propose a solution: by embedding multi-omics technology at each stage of immunogen
development, we can unlock a revolutionary increase in scale while simultaneously improving the depth and
resolution of our analyses. The Multi-Omics Vaccine Evaluation (MOVE) Consortium brings together a multi-
disciplinary team of expert investigators with a long history of productive collaboration. Our central hypothesis
is that deeply integrating advanced multi-omics approaches throughout our iterative vaccine development
pipeline will speed the discovery of an HIV vaccine by allowing us to operate concurrently across multiple
immunogens. Our overall mission is to accelerate development of an HIV vaccine by parallelizing the design
and testing of a matrix of complementary immunogens that reliably induce broad, durable immunity. To
accomplish our objectives, we propose the following Specific Aims:
Specific Aim 1: Profile the human immunogenicity of a novel V2 apex-focusing Env trimer.
Specific Aim 2: Evaluate Q23-elicited immune responses, candidate boosting immunogens, and delivery
strategies in humanized animal models.
Specific Aim 3: Develop the Q23 backbone into a multi-epitope priming immunogen.

## Key facts

- **NIH application ID:** 10852990
- **Project number:** 5P01AI177683-02
- **Recipient organization:** SCRIPPS RESEARCH INSTITUTE, THE
- **Principal Investigator:** Bryan Briney
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,778,269
- **Award type:** 5
- **Project period:** 2023-06-01 → 2028-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10852990

## Citation

> US National Institutes of Health, RePORTER application 10852990, The Multi-omics Vaccine Evaluation (MOVE) Consortium (5P01AI177683-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10852990. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*